HomeCompareDFIHY vs ABBV

DFIHY vs ABBV: Dividend Comparison 2026

DFIHY yields 12.74% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DFIHY wins by $2271733.66M in total portfolio value
10 years
DFIHY
DFIHY
● Live price
12.74%
Share price
$21.50
Annual div
$2.74
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2271733.76M
Annual income
$2,237,998,390,067.13
Full DFIHY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DFIHY vs ABBV

📍 DFIHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDFIHYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DFIHY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DFIHY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DFIHY
Annual income on $10K today (after 15% tax)
$1,083.26/yr
After 10yr DRIP, annual income (after tax)
$1,902,298,631,557.06/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DFIHY beats the other by $1,902,298,610,501.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DFIHY + ABBV for your $10,000?

DFIHY: 50%ABBV: 50%
100% ABBV50/50100% DFIHY
Portfolio after 10yr
$1135866.93M
Annual income
$1,118,999,207,419.44/yr
Blended yield
98.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DFIHY
No analyst data
Altman Z
4.4
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DFIHY buys
0
ABBV buys
0
No recent congressional trades found for DFIHY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDFIHYABBV
Forward yield12.74%3.06%
Annual dividend / share$2.74$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$2271733.76M$102.3K
Annual income after 10y$2,237,998,390,067.13$24,771.77
Total dividends collected$2269467.33M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DFIHY vs ABBV ($10,000, DRIP)

YearDFIHY PortfolioDFIHY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,249$2,548.84$11,550$430.00+$1.7KDFIHY
2$20,488$6,311.99$13,472$627.96+$7.0KDFIHY
3$40,167$18,244.81$15,906$926.08+$24.3KDFIHY
4$109,837$66,857.88$19,071$1,382.55+$90.8KDFIHY
5$459,249$341,723.52$23,302$2,095.81+$435.9KDFIHY
6$3,162,073$2,670,676.72$29,150$3,237.93+$3.13MDFIHY
7$37,754,350$34,370,931.76$37,536$5,121.41+$37.72MDFIHY
8$807,462,957$767,065,802.22$50,079$8,338.38+$807.41MDFIHY
9$31,528,383,856$30,664,398,492.61$69,753$14,065.80+$31528.31MDFIHY
10$2,271,733,760,793$2,237,998,390,067.13$102,337$24,771.77+$2271733.66MDFIHY

DFIHY vs ABBV: Complete Analysis 2026

DFIHYStock

DFI Retail Group Holdings Limited operates as a retailer in Asia. The company operates through five segments: Food, Health and Beauty, Home Furnishings, Restaurants, and Other Retailing. It primarily operates supermarkets and hypermarkets under the Wellcome, Yonghui, CS Fresh, MarketPlace, Giant, Hero, Mercato, Oliver's, 3hreesixty, San Miu, Jasons, and Lucky brands; and convenience stores under the 7-Eleven brand. The company also operates health and beauty stores under the Mannings, Guardian, and GNC brands; and home furnishings stores under the IKEA brand, as well as restaurants under the Maxim's brand. As of December 31, 2021, it operated 10,286 outlets in 12 Asian markets and territories. The company was formerly known as Dairy Farm International Holdings Limited and changed its name to DFI Retail Group Holdings Limited in May 2022. DFI Retail Group Holdings Limited was incorporated in 1886 and is based in Quarry Bay, Hong Kong. DFI Retail Group Holdings Limited is a subsidiary of Jardine Strategic Holdings Limited.

Full DFIHY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DFIHY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DFIHY vs SCHDDFIHY vs JEPIDFIHY vs ODFIHY vs KODFIHY vs MAINDFIHY vs JNJDFIHY vs MRKDFIHY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.